Competition Bureau Requires Elanco Divest Canine Otitis Product

The Competition Bureau entered into a consent agreement with Elanco Animal Health to address concerns related to the company’s proposed acquisition of Bayer Animal Health.

• Elanco also committed to forego acquiring Bayer AG’s Canadian distribution rights to several poultry insecticides
• Bureau concluded that Elanco and BAH are each other’s closest competitors in several Canadian markets
• The consent agreement requires Elanco to divest its canine otitis product, Osurnia, as well as BAH’s feline dewormer, Profender
• The consent agreement also notes Elanco’s commitment to forego acquiring the Canadian distribution rights to Bayer’s Tempo, Credo, QuickBaytand Annihilator Polyzone poultry insecticides

To view the ...